Medical

Magazine articles on health care providers, pharmaceutical companies, and medical technology.

Old Articles: <Older 1851-1860 Newer>

The Motley Fool March 9, 2005 Rich Duprey	Chiron Bundles Bad News The flu vaccine maker's bad news bonanza can't mask that it's overvalued.
Bio-IT World March 8, 2005 Mark D. Uehling	ABI Machine Reaches New Peak Applied Biosystems new API 5000 mass spec instrument is billed as the world's most sensitive for small molecules.
The Motley Fool March 8, 2005 Charly Travers	After the Crash, Is Biogen IDEC a Buy? Biogen stock plunge may be an overreaction to pulling multiple sclerosis drug Tysabri off the market.
The Motley Fool March 8, 2005 Stephen D. Simpson	The Stent Wars Continue Although Boston Scientific and Johnson & Johnson have been beating each other silly for market share, recent clinical data suggest little functional difference between drug-coated stents.
Bio-IT World March 8, 2005 John Russell	Debating Business Models for Bioinformatics Companies Nailing down a single formula for successfully selling bioinformatics products or services has proven elusive. Harvard Business School tackles informatics' basic question: Where's the money?
Bio-IT World March 8, 2005 Patricia Reilly	Biomarkers: Trends and Potential Companies are centralizing biomarker research to help reduce spending.
Bio-IT World March 8, 2005 John Russell	Entelos' Lofty Aspirations This is an interesting period for systems biology's wing of predictive biology companies. The label's luster is fading, but buoyed by pharma's growing interest, they are trying to figure out how to grow.
The Motley Fool March 7, 2005 Brian Gorman	Glaxo in Hot Water Glaxo's problems with the FDA could have been avoided. Investors can only hope that the FDA is in a forgiving mood.
The Motley Fool March 4, 2005 Tom Taulli	In the Express Scripts Lane Express Scripts' strong results bring a much-needed lift to health-care investors.
The Motley Fool March 4, 2005 Rich Duprey	Flamel Flames Out Again Nanotech regains rights to herpes treatment as partnership with pharma Biovail fails.
<Older 1851-1860 Newer> Return to current articles.